Kymriah Granted New Indication for Follicular Lymphoma
April 28, 2022Rinvoq Now Indicated for Ankylosing Spondylitis
April 29, 2022April 28, 2022 – AstraZeneca’s Ultomiris® (ravulizumab-cwvz) is now approved to treat generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive.
- Myasthenia gravis is a rare neuromuscular condition that causes severe weakness and loss of muscle function. Ultomiris is the first drug in its class approved to treat gMG.
- The FDA first approved Ultomiris in 2018. The drug is also indicated to treat paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome in patients at least one month of age.
- Recommended dosing is based on the patient’s diagnosis and body weight. To treat gMG, Ultomiris is administered via intravenous infusion once every eight weeks.